Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irpagratinib + ABSK043
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
irpagratinib + ABSK043 is a combination therapy being investigated for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC) with FGF19 overexpression. The combination consists of irpagratinib (ABSK-011), an oral, highly selective, and irreversible small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4), and ABSK043, an oral small molecule inhibitor of the programmed death-ligand 1 (PD-L1). Irpagratinib targets the FGF19-FGFR4 signaling axis, a known driver of tumor growth in a subset of HCC patients, while ABSK043 acts as an immune checkpoint inhibitor to restore the anti-tumor activity of T-cells. This combination approach aims to provide synergistic efficacy by simultaneously inhibiting oncogenic signaling and enhancing the immune response against the tumor.
- Other names
- irpagratinib + ABSK043
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on irpagratinib + ABSK043.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irpagratinib + ABSK043.